Prescient Therapeutics Ltd has released a press release.
PTX unveils CellPryme-A to boost CAR-T performance
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- PTX strategic collaboration with MD Anderson Cancer Center
- Prescient Therapeutics Launches Share Purchase Plan
- Appendix 4E and 2022 Annual Report
- PTX agreement with Thermo Fisher for scalable OmniCAR
- PTX OmniCAR cell manufacturing contract for clinical trials
Later from Prescient Therapeutics
- SPP Results and Placement
- Placement Results
- PTX-100 Trial Update
- September 2022 Quarterly Update and Appendix 4C
- AGM Presentation
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics